Pricing Log in Create free account
Friday 6 November 2026 Export UTMD’s income statement to Excel — free account

Utah Medical Products, Inc.

UTMD Healthcare Medical Instruments & Supplies

Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024.

Revenue
−14.3%
EPS
−10.6%
Free cash flow
−55.7%

Quarter to June 2026, against a year earlier

71.10 1.32 −1.82%
Market cap
$202.4M
P/E
21.7×
Fwd P/E
28.7×
Dividend yield
1.74%
F-score
6/9
Altman Z
36.25
Beneish M
−2.68
Dividend safety
82/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.07
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — 1 —
Sell — — — — — — — — — — — —
Insider Ownership 7.35%

Capital & Financial Ratios $m

Size
Market Cap 202.40
Revenue ttm 36.11
Net income ttm 10.49
Free cash flow ttm 11.45
Net debt Q (87.53)
Valuation
P/E 21.68
Forward P/E 28.70
Price / sales 6.27
Forward P/S Powerpack
Price / FCF 19.78
Price / book 1.86
Financial health
Current ratio Q 48.62 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q −14.31% (below 0%: shrinking)
Operating income growth Q −17.12% (below 0%: shrinking)
EPS, this year —
EPS, next year A —
Revenue, next year A −10.03% (below 0%: weak)
EPS, past 5 yrs +3.43%
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.9×, against a ten-year median of 5.3×; over the ten years it ranged from 2.3× in 2025 to 8.8× in 2018.
P/E against its own 10 years 65.02%
10-year low 10-year high
P/S against its own 10 years 43.31%
10-year low 10-year high
P/B against its own 10 years 16.57%
10-year low 10-year high
EV/Sales against its own 10 years 23.62%
10-year low 10-year high
EV/FCF against its own 10 years 44.02%
10-year low 10-year high

Dividends

Yield
1.74%
Annual rate
1.24
Payout ratio
37.8%
Growth, 2018–26
−1.91%/yr
  1. 1.09 ’18
  2. 1.11 ’19 +2
  3. 1.13 ’20 +2
  4. 0.86 ’21 −24
  5. 1.17 ’22 +36
  6. 1.19 ’23 +2
  7. 1.21 ’24 +2
  8. 1.23 ’25 +2
  9. 0.93 ’26 −24
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 93 83 86 88
Receivables 3 4 4 4
Inventory 10 9 8 9
Other — — — —
106 96 98 101
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other — — — —
5 4 3 2

Compound Annual Growth %

10y 5y 3y
Sales (0.42%) (1.80%) (9.68%)
Cash Flow 0.63% (6.11%) (11.43%)
Earnings (0.48%) 0.89% (11.84%)
Book Value 5.53% 3.01% 1.44%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY13 Estimate 0.69 Actual 0.68

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY13 0.69 0.68 Miss by 0.01

EPS $

Mar Jun Sep Dec Year
’26 0.82 0.84 — — —
’25 0.92 0.94 0.82 0.80 3.48
’24 1.09 0.98 1.02 0.86 3.96
’23 1.16 1.15 1.08 1.18 4.57
’22 0.96 1.12 1.18 1.25 4.52
’21 0.83 0.94 1.15 1.13 4.04
’20 0.84 0.36 0.80 0.93 2.94
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 9 9 — — —
’25 10 10 10 9 39
’24 11 10 10 9 41
’23 13 13 13 12 50
’22 12 13 13 14 52
’21 11 13 13 13 49
’20 11 9 10 12 42
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3 1 — — —
’25 4 3 4 3 15
’24 5 3 4 3 15
’23 7 5 5 5 22
’22 5 5 6 6 21
’21 6 5 6 5 21
’20 6 4 5 6 20
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 1 — — —
’25 4 3 4 3 14
’24 5 3 4 3 15
’23 7 5 5 5 22
’22 5 5 5 6 20
’21 6 4 6 5 21
’20 5 3 5 6 19
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 39 41 42 47 42 49 52 50 41 39 36 (0.2%) — — — —
Gross margin, % 60.28 63.73 62.64 62.82 60.57 63.03 61.58 59.81 59.03 57.12 57.90 (3.2) pt
EBT 16 19 19 18 14 19 21 20 17 14 13 (1.7%)
EBT margin, % 41.79 46.08 46.33 38.13 32.81 38.86 39.52 40.00 41.08 36.63 35.68 (5.2) pt
Net income 12 9 19 15 11 15 16 17 14 11 10 (0.8%)
Per share, $
Per share, $ Revenue 10.48 11.14 11.26 12.61 11.53 13.45 14.37 13.84 11.68 11.89 11.34 +1.4%
Earnings 3.22 2.28 4.95 3.94 2.94 4.04 4.52 4.57 3.96 3.48 3.28 +0.9%
Cash flow 3.87 4.55 4.51 4.58 5.50 5.81 5.81 6.14 4.23 4.53 3.72 +1.8%
Capex (0.88) (0.43) 0.12 (5.79) (0.24) (0.15) (0.22) (0.18) (0.06) (0.11) (0.13) (20.3%)
Free cash flow 2.99 4.12 4.64 (1.21) 5.27 5.66 5.59 5.96 4.17 4.42 3.60 +4.4%
Book value 18.46 21.01 23.86 27.17 28.11 29.38 31.41 35.36 33.52 36.81 38.33 +8.0%
Shares, m 4 4 4 4 4 4 4 4 4 3 3 (1.6%)
Valuation, ×
Valuation, × P/E 22.24 34.63 16.78 27.39 28.77 24.69 21.68 18.27 15.56 16.08 21.68 22.6
P/S 6.82 7.12 7.38 8.56 7.31 7.43 6.80 6.03 5.26 4.71 6.27 6.7
P/B 3.87 3.77 3.48 3.97 3.00 3.40 3.11 2.36 1.83 1.52 1.86 3.0
EV/Sales 6.17 6.18 6.18 7.67 6.11 6.21 5.38 4.20 3.26 2.51 3.87 5.4
EV/FCF 21.60 16.72 15.02 (80.21) (149.60) (873.06) 13.85 9.75 9.12 6.74 12.22 (101.0)
Cash, $m
Cash, $m Operating cash flow 15 17 17 17 20 21 21 22 15 15 12 +0.1%
Capex (3) (2) 0 (22) (1) (1) (1) (1) 0 0 0 (21.6%)
Free cash flow 11 15 17 (4) 19 21 20 22 15 14 11 +2.7%
Balance, $m
Balance, $m Working capital 31 44 56 51 58 69 84 102 93 95 99 +13.1%
Net debt (26) (40) (51) (43) (52) (61) (75) (93) (83) (86) (88) +14.0%
Shareholders’ equity 69 78 89 101 103 107 114 128 117 119 122 +6.2%
Returns, %
Returns, % ROA 15.61 10.07 19.28 14.06 9.75 13.01 13.76 12.83 10.76 9.21 8.55 (6.4) pt
ROIC 23.59 31.13 30.85 18.90 16.72 25.56 31.55 29.58 24.66 21.26 18.60 (2.3) pt
ROE 17.46 11.54 22.21 15.50 10.59 14.09 14.88 13.72 11.29 9.54 8.75 (7.9) pt
People
People Employees 184 183 173 193 192 211 221 190 167 152 — (2.1%)
Revenue/emp, $m 0.21 0.23 0.24 0.24 0.22 0.23 0.24 0.26 0.24 0.25 — +1.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Utah Medical Products, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NNNN Anbio Biotechnology $516.6M — — — — — — — Compare
ZJYL Jin Medical International Ltd. $509.4M — — — — −8,074.17% (below 0%: shrinking) 34.44% 0.00% Compare
ANGO AngioDynamics, Inc. $496.7M — (loss-making) — (loss-making) +6.87% (above 0%: growing) n/m +5.62% (above 0%: growing) 59.37% (9.02%) Compare
EMBC Embecta Corp. $358.7M 4.2× 5.3× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92% Compare
SMTI Sanara MedTech Inc. $290.4M — (loss-making) 164× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33% Compare
OSUR OraSure Technologies, Inc. $232.4M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76% Compare
UTMD Utah Medical Products, Inc. $202.4M 21.7× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06%
PDEX Pro-Dex, Inc. $195.8M 16.4× 18.8× +10.96% (above 0%: growing) −33.57% (below 0%: shrinking) +177.76% (above 0%: growing) 33.35% 17.10% Compare
KRMD KORU Medical Systems, Inc. $139.9M — (loss-making) — (loss-making) +18.15% (above 0%: growing) n/m +26.17% (above 0%: growing) 65.14% 5.21% Compare
Median of peers $324.5M — 18.8× +7.96% — +5.62% 56.42% 6.33%

All 53 Medical Instruments & Supplies stocks →

Utah Medical Products, Inc. (UTMD) Latest News

29 Oct

Impact 3 · · ACCESS Newswire
Impact 3 · · Zacks

28 Oct

Impact 3 · · Zacks

24 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

22 Oct

Impact 4 · · ACCESS Newswire

8 Oct

Impact 3 · · Zacks

5 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · ACCESS Newswire

25 Sep

Impact 3 · · ACCESS Newswire

24 Sep

Impact 3 · · ACCESS Newswire

15 Sep

Impact 4 ·

31 Aug

Impact 3 ·

29 Jul

Impact 3 ·

23 Jul

Impact 3 ·

23 Apr

Impact 3 · · ACCESS Newswire

4 Feb

Impact 3 · · ZacksAssociated Press FinanceMedical Device NetworkZacksZacks

29 Jan

Impact 4 ·
Impact 3 · · Associated Press Finance earnings

25 Jan

Impact 3 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

28 Dec

Impact 3 · · Simply Wall St.

11 Dec

Impact 3 · · Simply Wall St.

8 Nov

Impact 3 · · Simply Wall St.

4 Nov

Impact 3 ·

23 Oct

Impact 4 · · Associated Press FinanceSimply Wall St.Associated Press FinanceAssociated Press FinanceMT NewswiresMT NewswiresAssociated Press FinanceZacks
Impact 4 · · ACCESS Newswire

18 Aug

Impact 3 · · Simply Wall St.

1 Aug

Impact 3 · · Simply Wall St.

30 Jul

Impact 3 · · Zacks

25 Jul

Impact 4 ·
stockrow.com/UTMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com